173 related articles for article (PubMed ID: 19387419)
1. Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans.
Xiang X; Han Y; Neuvonen M; Pasanen MK; Kalliokoski A; Backman JT; Laitila J; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2009 Jun; 19(6):447-57. PubMed ID: 19387419
[TBL] [Abstract][Full Text] [Related]
2. Gender, but not CYP7A1 or SLCO1B1 polymorphism, affects the fasting plasma concentrations of bile acids in human beings.
Xiang X; Backman JT; Neuvonen PJ; Niemi M
Basic Clin Pharmacol Toxicol; 2012 Mar; 110(3):245-52. PubMed ID: 21902813
[TBL] [Abstract][Full Text] [Related]
3. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.
Pasanen MK; Neuvonen M; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2006 Dec; 16(12):873-9. PubMed ID: 17108811
[TBL] [Abstract][Full Text] [Related]
4. No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.
Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2008 Jan; 65(1):78-86. PubMed ID: 17635496
[TBL] [Abstract][Full Text] [Related]
5. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
Niemi M; Pasanen MK; Neuvonen PJ
Clin Pharmacol Ther; 2006 Oct; 80(4):356-66. PubMed ID: 17015053
[TBL] [Abstract][Full Text] [Related]
6. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism.
He YJ; Zhang W; Chen Y; Guo D; Tu JH; Xu LY; Tan ZR; Chen BL; Li Z; Zhou G; Yu BN; Kirchheiner J; Zhou HH
Clin Chim Acta; 2009 Jul; 405(1-2):49-52. PubMed ID: 19374892
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate.
Pasanen MK; Miettinen TA; Gylling H; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2008 Oct; 18(10):921-6. PubMed ID: 18794729
[TBL] [Abstract][Full Text] [Related]
8. The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.
Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2008 Dec; 66(6):818-25. PubMed ID: 18823304
[TBL] [Abstract][Full Text] [Related]
9. No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid.
Xiang X; Vakkilainen J; Backman JT; Neuvonen PJ; Niemi M
Eur J Clin Pharmacol; 2011 Nov; 67(11):1159-67. PubMed ID: 21655991
[TBL] [Abstract][Full Text] [Related]
10. SLCO1B1 polymorphism and oral antidiabetic drugs.
Kalliokoski A; Neuvonen PJ; Niemi M
Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):775-81. PubMed ID: 20406215
[TBL] [Abstract][Full Text] [Related]
11. Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition.
Shen H; Christopher L; Lai Y; Gong J; Kandoussi H; Garonzik S; Perera V; Garimella T; Humphreys WG
Drug Metab Dispos; 2018 Aug; 46(8):1075-1082. PubMed ID: 29777022
[TBL] [Abstract][Full Text] [Related]
12. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.
Kalliokoski A; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
Clin Pharmacol Ther; 2008 Oct; 84(4):488-96. PubMed ID: 19238654
[TBL] [Abstract][Full Text] [Related]
13. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
J Clin Pharmacol; 2008 Mar; 48(3):311-21. PubMed ID: 18187595
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes.
Hedman M; Antikainen M; Holmberg C; Neuvonen M; Eichelbaum M; Kivistö KT; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2006 Jun; 61(6):706-15. PubMed ID: 16722833
[TBL] [Abstract][Full Text] [Related]
15. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
[TBL] [Abstract][Full Text] [Related]
16. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
[TBL] [Abstract][Full Text] [Related]
17. Establishment of an expression platform of OATP1B1 388GG and 521CC genetic polymorphism and the therapeutic effect of tamoxifen in MCF-7 cells.
Pu Z; Zhang X; Chen Q; Yuan X; Xie H
Oncol Rep; 2015 May; 33(5):2420-8. PubMed ID: 25812934
[TBL] [Abstract][Full Text] [Related]
18. Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Kalliokoski A; Backman JT; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2008 Nov; 18(11):937-42. PubMed ID: 18854776
[TBL] [Abstract][Full Text] [Related]
19. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide.
Zhang W; He YJ; Han CT; Liu ZQ; Li Q; Fan L; Tan ZR; Zhang WX; Yu BN; Wang D; Hu DL; Zhou HH
Br J Clin Pharmacol; 2006 Nov; 62(5):567-72. PubMed ID: 16796707
[TBL] [Abstract][Full Text] [Related]
20. SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid.
Tornio A; Vakkilainen J; Neuvonen M; Backman JT; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2015 Aug; 25(8):382-7. PubMed ID: 26020121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
